2009 onwards
- Academic research commenced at Imperial College, London
- Six clinical biomarker discovery trials completed (n=2,352; 580 with cancer)
- Addressed sample collection and processing issues including contamination
- Generated several patents and other IP
- SpiraCheck founded in 2016
2021-2023
- Raised £1m
- Hired CEO
- Ten Imperial College-led studies started (>30,000 patients)
- Appointed CFO
- SpiraCheck Series A fundraising commenced
2024-2025
- Design and development - to Standards required by global regulations
- CE/UKCA mark sample collection devices
- Establish first commercial lab
- Achieve SpiraCheck QMS certification
- Fundraising
2026...
- Commence first validation/pivotal study
- Regulatory approval of test for initial indication
- Launch initial indication device
- Complete development of platform device for validation/pivotal study
- Establish further national labs
